Cargando…

Durvalumab: First report of minimal change disease: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813494/ http://dx.doi.org/10.1007/s40278-022-09644-0

Ejemplares similares

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

Durvalumab/elasomeran: Immune thrombocytopenia: case report
Publicado: (2022)

Durvalumab: Immune-related pneumonitis: case report
Publicado: (2021)

Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report
por: Kanaoka, Kensuke, et al.
Publicado: (2020)

Durvalumab/everolimus: Lung toxicity and pulmonary sarcoidosis: 2 case reports
Publicado: (2021)

Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
por: Cham, Jason, et al.
Publicado: (2021)

Elasomeran: Minimal change disease: case report
Publicado: (2022)

Minimal change disease following the Moderna COVID-19 vaccine: first case report
por: Thappy, Shaefiq, et al.
Publicado: (2021)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report
por: Mahmood, Syed S., et al.
Publicado: (2018)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
por: Tonk, Erwin H.J., et al.
Publicado: (2019)

Minimal Change Disease in an Adult: A Case Report
por: Neupane, Shashank, et al.
Publicado: (2022)

mrna-1273: Minimal change disease: case report
Publicado: (2021)

Long‐term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report
por: Yorozuya, Takafumi, et al.
Publicado: (2020)

Hyperprogressive disease in lung metastases without target lesion progression after durvalumab consolidation therapy: A case report
por: Masuda, Kosuke, et al.
Publicado: (2023)

Tozinameran: Nephrotic syndrome and minimal change disease : case report
Publicado: (2022)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: A Case Report and Literature Review
por: Pratumchart, Nathathai, et al.
Publicado: (2022)

Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report
por: Moodie, Travis, et al.
Publicado: (2022)

Myositis induced by durvalumab in a patient with non‐small cell lung cancer: A case report
por: Kobayashi, Miyuki, et al.
Publicado: (2020)

Celecoxib/cloxacillin/durvalumab: Lichen or bullous pemphigoid-like eruption and acute tubulointerstitial nephritis: case report
Publicado: (2021)

Benefits from standalone durvalumab treatment in an elderly patient with advanced prostatic sarcoma: a case report
por: Wang, Lili, et al.
Publicado: (2021)

Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
por: Zhang, Cuifen, et al.
Publicado: (2023)

IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report
por: Terashima, Takeshi, et al.
Publicado: (2020)

AZD-1222: Glomerulonephritis secondary to minimal change disease: case report
Publicado: (2022)

Prostate Cancer Associated with Minimal Change Disease: A Case Report
por: Nakano, Yuta, et al.
Publicado: (2022)

Minimal change disease caused by polycythemia vera: A case report
por: Xu, Li, et al.
Publicado: (2022)

Azd-1222: Relapse of minimal change disease: 2 case reports
Publicado: (2021)

Efficacy of rituximab in thymoma associated minimal change disease: case report
por: El Ouafi, Zhour, et al.
Publicado: (2021)

Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine
por: Hanna, Jessica, et al.
Publicado: (2021)

Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report
por: Lopes, Ana Rita, et al.
Publicado: (2020)

The first description of severe anemia associated with acute kidney injury and adult minimal change disease: a case report
por: Qian, Yimei, et al.
Publicado: (2009)

Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report
por: Chen, Hao Xiang, et al.
Publicado: (2022)

A case of durvalumab-induced lichenoid eruption evolving to bullous eruption after phototherapy: A case report
por: Manko, Svitlana, et al.
Publicado: (2021)

Minimal change disease with concurrent thin basement membrane disease: A case report
por: Alroshodi, Abdulaziz I.
Publicado: (2020)

AZD-1222: Minimal change disease and acute kidney injury: case report
Publicado: (2021)

Covid-19-vaccine-pfizer-biontech: Minimal change disease: case report
Publicado: (2021)

Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report
por: Nishino, Kazumi, et al.
Publicado: (2020)

Strongyloides—An uncommon cause of eosinophilia whilst on durvalumab
por: Quah, Gaik Tin, et al.
Publicado: (2022)

Durvalumab-associated generalized morphea with overlapping vitiligo
por: Martel, Julianna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i0rheom1n0mulnq54gum6babd5